Scholarlink

<p>Molecular therapies targeting the EGFR/MAPK pathway have improved outcomes in colorectal cancer (CRC), yet acquired resistance remains a major clinical challenge. Oncogenic signaling can activate stress response pathways that sustain tumor survival under therapeutic pressure. Among these, the DNA damage response (DDR) maintains genomic integrity and may represent a targetable vulnerability in resistant tumors. To investigate this, we developed a preclinical platform of CRC models with acquired resistance to anti-EGFR agents (“ARes platform”). A targeted pharmacological screen of DDR inhibitors identified WEE1 kinase as a leading therapeutic candidate. Validation in xenograft models and patient-derived organoids confirmed that anti-EGFR-resistant CRCs retained, and in some cases increased, sensitivity to WEE1 inhibition. Mechanistically, resistant cells exhibited elevated DNA damage, heightened replication stress, and accelerated mitotic entry, culminating in cell death upon WEE1 blockade. These findings establish WEE1 as a promising therapeutic target in CRC with acquired resistance to EGFR inhibition and support the clinical evaluation of WEE1 inhibitors, alone or combined with DNA-damaging agents, for patients progressing on anti-EGFR–based therapies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

WEE1 kinase inhibition to overcome acquired resistance to targeted therapies in colorectal cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月19日

查看全文
  • Kristi Buzo,
  • Laura Bizzozero,
  • Marilena Lentini,
  • Alena Opattova,
  • Beatriz Hernández-Suárez,
  • Michael Torres,
  • Giulia Chiabotto,
  • Clelia Nisticò,
  • Giada De Lazzari,
  • Eugenia R Zanella,
  • Gaia Grasso,
  • Elisa Mariella,
  • Erika Durinikova,
  • Michael Linnebacher,
  • Andrea Sartore-Bianchi,
  • Salvatore Siena,
  • Livio Trusolino,
  • Alberto Bardelli,
  • Sabrina Arena

摘要

Molecular therapies targeting the EGFR/MAPK pathway have improved outcomes in colorectal cancer (CRC), yet acquired resistance remains a major clinical challenge. Oncogenic signaling can activate stress response pathways that sustain tumor survival under therapeutic pressure. Among these, the DNA damage response (DDR) maintains genomic integrity and may represent a targetable vulnerability in resistant tumors. To investigate this, we developed a preclinical platform of CRC models with acquired resistance to anti-EGFR agents (“ARes platform”). A targeted pharmacological screen of DDR inhibitors identified WEE1 kinase as a leading therapeutic candidate. Validation in xenograft models and patient-derived organoids confirmed that anti-EGFR-resistant CRCs retained, and in some cases increased, sensitivity to WEE1 inhibition. Mechanistically, resistant cells exhibited elevated DNA damage, heightened replication stress, and accelerated mitotic entry, culminating in cell death upon WEE1 blockade. These findings establish WEE1 as a promising therapeutic target in CRC with acquired resistance to EGFR inhibition and support the clinical evaluation of WEE1 inhibitors, alone or combined with DNA-damaging agents, for patients progressing on anti-EGFR–based therapies.